You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Diffuse Large B-Cell Lymphoma: Evolution of Treatment Approaches

  • Authors: Christopher R. Flowers, MD, MS, FASCO; Caron Jacobson, MD; Gilles Salles, MD, PhD
  • CME / ABIM MOC Released: 7/13/2022
  • Valid for credit through: 7/13/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists, nurses, and nurse practitioners (NPs)/physician assistants (PAs).

The goal of this activity is that learners will be better able to manage patients with DLBCL and integrate emerging approaches to treatment in practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Limitations of the current standard of care for the frontline treatment of DLBCL
    • Emerging approaches to frontline treatment for DLBCL
    • Treatment options for patients with R/R DLBCL
  • Have increased confidence in their ability to
    • Select appropriate therapy for patients with DLBCL based on patient- and disease-specific factors


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Christopher R. Flowers, MD, MS, FASCO

    Chair and Professor
    Department of Lymphoma/Myeloma
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Christopher R. Flowers, MD, MS, FASCO, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Bayer; BeiGene; Celgene; Denovo Biopharma; Epizyme; Genentech/Roche; Genmab; Gilead; Karyopharm; Pharmacyclics/Janssen; SeaGen, Inc., formerly Seattle Genetics, Inc.; Spectrum
    Research funding from: 4D; AbbVie; Acerta; Adaptimmune; Allogene; Amgen; Bayer; Celgene; Cellectis; EMD; Gilead; Genentech/Roche; Guardant; Iovance; Janssen Pharmaceutical; Kite; Morphosys; Nektar; Novartis; Pfizer; Pharmacyclics; Sanofi; Takeda; TG Therapeutics; Xencor; Ziopharm

Faculty

  • Caron Jacobson, MD

    Assistant Professor of Medicine
    Harvard Medical School
    Medical Director
    Immune Effector Cell Therapy Program
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Disclosures

    Caron Jacobson, MD, has the following relevant financial relationships:
    Consultant or advisor for: Bluebird Bio; Bristol Myers Squibb/Celgene; Epizyme; Instill Bio; Ipsen; Kite/Gilead; Lonza; Novartis
    Speaker or member of speakers bureau for: PleXus
    Research funding from: Kite/Gilead; Pfizer

  • Gilles Salles, MD, PhD

    Professor of Medicine
    Chief of the Lymphoma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Gilles Salles, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Bayer; BeiGene; Bristol Myers Squibb; Celgene; Debiopharm; Epizyme; Everest Clinical Research Corporation; Genentech; GenMab; Gilead Pharmaceuticals; Ipsen; Loxo Oncology; Miltenyi Biotec Incorporated; MorphoSys AG; Nordic Nanovector; Novartis; RAPT Therapeutics; Regeneron Pharmaceuticals; Roche; Takeda Millennium; VelosBio, Inc
    Owns stock (privately owned) in: Owkin, Inc

Editor

  • Megan Whitney, DMD

    Medical Education Director, Medscape, LLC

    Disclosures

    Megan Whitney, DMD, has no relevant financial relationships.

  • Yoji Yamaguchi, MA, ELS

    Scientific Content Manager, Medscape, LLC

    Disclosures

    Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Diffuse Large B-Cell Lymphoma: Evolution of Treatment Approaches

Authors: Christopher R. Flowers, MD, MS, FASCO; Caron Jacobson, MD; Gilles Salles, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 7/13/2022

Valid for credit through: 7/13/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to manage patients with DLBCL and integrate emerging approaches to treatment in practice.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and compare your answers with those of your peers.

  • Print